Eyecare Innovations Today: An Ophthalmic Educational Podcast Series

The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

11 min · 4 de jun de 2024
Portada del episodio The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

Descripción

In this episode, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management. This activity is supported by an independent medical education grant from Théa Pharma.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Eyecare Innovations Today: An Ophthalmic Educational Podcast Series!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

65 episodios

episode The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer artwork

The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

In this episode, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management. This activity is supported by an independent medical education grant from Théa Pharma.

4 de jun de 202411 min